Erectile Dysfunction - Read the latest Erectile Dysfunction research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Dr. Abhilash Moolupuri presented the initial exploratory and phase I/II results of a trial evaluating a novel PSMA-targeting ...

UroToday's exclusive Video Lecture coverage of ASCO 2025 Conference Videos ...

This study, presented at SNMMI 2025, aimed to further evaluate the safety profile and determine the optimal therapeutic dose of 177 Lu-P17-088, while also exploring its preliminary efficacy in the ...

The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 7: Non-metastatic ...

R. Jonathan Henderson summarized key principles for managing biochemically recurrent prostate cancer, emphasizing the importance of risk stratification and life expectancy in treatment decisions.

June 4, 2025 Previous research on Radium-223 treatment patterns in metastatic prostate cancer has been limited to select sites, oncology practices, or claims databases. Limited data exists on the use ...

Interdisciplinary Genitourinary Cancer Forum featured a metastatic urothelial carcinoma session and a presentation by Dr.

Neeraj Agarwal is joined by Wolfgang Fendler to discuss PSMA PET prognostication data. Dr. Fendler's international consortium of 50 sites analyzed 6,000 patients to develop risk stratification models ...

APCCC 2024: Patient Selection for Radioligand Therapy: How to Do It in Clinical Practice and How to Decide on the Number of Cycles. APCCC 2024: Dosing of Radioligand Therapy in Special Situations ...

In one patient, total body scans were performed at 15 minutes, 1 hour, 2 hours, and 4 hours post-injection. The effective dose was 0.022 mSv/MBq, with the stomach wall receiving the highest organ dose ...

(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Benjamin Garmezy discussing a phase 1 trial of mevrometostat (PF-06821497), a potent and ...